U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Magnolia Medical Technologies, Inc. - 617922 - 05/04/2022
  1. Warning Letters

CLOSEOUT LETTER

Magnolia Medical Technologies, Inc. MARCS-CMS 617922 —

Delivery Method:
VIA Electronic Mail
Product:
Medical Devices
Recipient:
Recipient Name
Gregory J. Bullington
Recipient Title
CEO
Magnolia Medical Technologies, Inc.

200 W. Mercer St
Suite 500
Seattle, WA 98119
United States

Greg.bullington@magnolia-medical.com
Issuing Office:
Office of Medical Devices and Radiological Health, Division 3

United States

Dear Mr. Bullington:

The Food and Drug Administration has completed an evaluation of your corrective actions in response to our Warning Letter dated September 17, 2021. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Jessica Mu
Director, Compliance Branch
Office of Medical Devices and Radiological Health, Division III

Back to Top